Enlivex Therapeutics

OverviewSuggest Edit

Enlivex Therapeutics (previously known as Bioblast Pharma) is a clinical-stage company focused on specialized cell immunotherapy. It develops and commercializes an allogeneic drug pipeline for the rebalancing manner of immune hyper-responses. The company offers Allocetra, a cell-based therapy designed to treat acute conditions. 

TypePublic
Founded2012
HQNess Ziona, IL
Websiteenlivex.com

Latest Updates

Employees (est.) (Dec 2019)36(+17%)
Revenue (FY, 2017)$0
Share Price (Sept 2020)$5.3
Cybersecurity ratingAMore

Key People/Management at Enlivex Therapeutics

Shai Novik

Shai Novik

Executive Chairman
Oren Hershkovitz

Oren Hershkovitz

Chief Executive Officer
Dror Mevorach

Dror Mevorach

Chief Scientific & Medical Officer
Shachar Shlosberger

Shachar Shlosberger

CFO
Show more

Enlivex Therapeutics Office Locations

Enlivex Therapeutics has an office in Ness Ziona
Ness Ziona, IL (HQ)
Einstein St 14
Show all (1)

Enlivex Therapeutics Financials and Metrics

Enlivex Therapeutics Revenue

USD

Net income (FY, 2019)

(9.4m)

EBIT (FY, 2019)

(8.6m)

Market capitalization (18-Sept-2020)

71.5m

Closing stock price (18-Sept-2020)

5.3

Cash (31-Dec-2019)

3.9m
Enlivex Therapeutics's current market capitalization is $71.5 m.
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

Sales and marketing expense

829.0k1.1m479.0k

General and administrative expense

7.0m5.9m3.0m1.8m2.9m

R&D expense

7.7m8.9m2.5m310.0k5.7m
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

10.6m7.3m6.9m3.5m377.0k3.9m

Accounts Receivable

93.0k16.0k403.0k

Prepaid Expenses

181.0k1.1m663.0k96.0k510.0k

Current Assets

32.9m20.4m10.5m3.6m865.0k16.4m
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(7.0m)(15.4m)(16.0m)(5.9m)(2.1m)(9.4m)

Depreciation and Amortization

5.0k17.0k38.0k64.0k206.0k

Accounts Payable

1.2m107.0k129.0k(790.0k)(3.0k)114.0k

Cash From Operating Activities

(4.4m)(13.2m)(15.5m)(6.4m)(3.1m)(7.0m)
USDFY, 2014

Financial Leverage

1.1 x
Show all financial metrics

Enlivex Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Enlivex Therapeutics Online and Social Media Presence

Embed Graph

Enlivex Therapeutics News and Updates

Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma

Diversifies Seelos’ pipeline in rare diseases

Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics

Tel Aviv, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. ( Nasdaq: ORPN),  a clinical-stage, orphan disease-focused biotechnology company, today announced the sale of its Trehalose clinical development programs (including its advanced phase 2 clinical program of Trehalose to treat…

Bioblast Pharma Announces Collaboration with Team Sanfilippo to Evaluate Trehalose for the Treatment of Sanfilippo Syndrome

Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome today…

Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance

Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq …

Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors

TEL AVIV, Israel, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq: ORPN) announced the execution of a definitive agreement to acquire Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. Upon closing of the transaction, the combined company will change its na…

Enlivex Therapeutics Frequently Asked Questions

  • When was Enlivex Therapeutics founded?

    Enlivex Therapeutics was founded in 2012.

  • Who are Enlivex Therapeutics key executives?

    Enlivex Therapeutics's key executives are Shai Novik, Oren Hershkovitz and Dror Mevorach.

  • How many employees does Enlivex Therapeutics have?

    Enlivex Therapeutics has 36 employees.

  • Who are Enlivex Therapeutics competitors?

    Competitors of Enlivex Therapeutics include Inovio Pharmaceuticals, Marinus Pharmaceuticals and Alimera Sciences.

  • Where is Enlivex Therapeutics headquarters?

    Enlivex Therapeutics headquarters is located at Einstein St 14, Ness Ziona.

  • Where are Enlivex Therapeutics offices?

    Enlivex Therapeutics has an office in Ness Ziona.

  • How many offices does Enlivex Therapeutics have?

    Enlivex Therapeutics has 1 office.